CLINICAL TRIALS PROFILE FOR VECURONIUM BROMIDE

All Clinical Trials for vecuronium bromide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00970762 ↗	Comparative Study of Rocuronium With Vecuronium (Study 71101)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2003-02-01	This study was conducted to determine and compare the safety and effectiveness of two neuromuscular blockers (rocuronium and vecuronium) at various doses in adults who are undergoing general elective surgery with sevoflurane anesthesia. Study participants received an intubating dose of a neuromuscular blocker (to enable insertion of a tube through the nose or mouth into the trachea to provide artificial ventilation). The intubating dose was followed by repeated bolus maintenance doses as needed, to maintain muscle relaxation. The time it takes to reach maximal effect of the neuromuscular blocker (onset time) after the intubating dose was measured and compared as the primary outcome.
NCT01116713 ↗	Effect of Dexamethasone in Postoperative Symptoms After Mastectomy for Breast Cancer	Completed	Instituto Mexicano del Seguro Social	Phase 3	2009-06-01	Postoperative pain, nausea and vomiting (PONV) are the most common complications after anesthesia and surgery. Women undergoing mastectomy with axillary dissection are at a particularly high risk for the development of PONV and an incidence of 60-80% in patients receiving no antiemetic has been reported. Emetic episodes predispose to aspiration of gastric contents, wound dehiscence, psychological distress, and delayed recovery and discharge times. These justify the use of prophylactic antiemetics in women scheduled for mastectomy. Most of the currently used antiemetics, including antihistamines, butyrophenones and dopamine receptor antagonists have been reported to cause occasional undesirable adverse effects, such as excessive sedation, hypotension, dry mouth, dysphoria, hallucinations and extrapyramidal signs. Antiserotonins (e.g., ondansetron) are available for the prevention and treatment of PONV in patients undergoing various types of surgery [4]. However, the use of prophylactic antiemetic therapy with antiserotonins has been criticized for being too expensive. Dexamethasone was first reported to be an effective antiemetic regimen in patients receiving cancer chemotherapy. The purpose of this study was to evaluate the efficacy of dexamethasone treatment for reducing pain and PONV as well as analgesic and antiemetic requirements in women undergoing general anesthesia for mastectomy with axillary lymph node dissection.
NCT01690338 ↗	A Study of Residual Curarization Incidence in China	Unknown status	Central South University	Phase 4	2012-10-01	The purpose of this study is to determine the incidence of residual curarization in PACU and relevant risk factors.
NCT01690338 ↗	A Study of Residual Curarization Incidence in China	Unknown status	China Medical University Hospital	Phase 4	2012-10-01	The purpose of this study is to determine the incidence of residual curarization in PACU and relevant risk factors.

Clinical Trial Conditions for vecuronium bromide

Condition Name

Condition Name for vecuronium bromide
Intervention	Trials
Anesthesia	4
Reversal of Neuromuscular Blockade	3
Residual Neuromuscular Block	2
Neuromuscular Blocking Agents	2

Condition MeSH

Condition MeSH for vecuronium bromide
Intervention	Trials
Delayed Emergence from Anesthesia	3
Body Weight	1
Respiratory Distress Syndrome	1
Vomiting	1

Clinical Trial Locations for vecuronium bromide

Trials by Country

Trials by Country for vecuronium bromide
Location	Trials
United States	30
China	13
Austria	3
Denmark	2
India	2

Trials by US State

Trials by US State for vecuronium bromide
Location	Trials
Wisconsin	2
Texas	2
Tennessee	2
Pennsylvania	2
Ohio	2

Clinical Trial Progress for vecuronium bromide

Clinical Trial Phase

Clinical Trial Phase for vecuronium bromide
Clinical Trial Phase	Trials
PHASE4	2
Phase 4	8
Phase 3	2

Clinical Trial Status

Clinical Trial Status for vecuronium bromide
Clinical Trial Phase	Trials
Completed	7
Unknown status	4
NOT_YET_RECRUITING	2

Clinical Trial Sponsors for vecuronium bromide

Sponsor Name

Sponsor Name for vecuronium bromide
Sponsor	Trials
Merck Sharp & Dohme Corp.	3
The First Affiliated Hospital of Zhengzhou University	2
Postgraduate Institute of Medical Education and Research	2

Sponsor Type

Sponsor Type for vecuronium bromide
Sponsor	Trials
Other	47
Industry	3

Vecuronium bromide Market Analysis and Financial Projection

Last updated: April 28, 2026

Vecuronium Bromide: Clinical Trial Update, Market Analysis, and 5-Year Projection

What is vecuronium bromide and where is it used clinically?

Vecuronium bromide is a non-depolarizing neuromuscular blocking agent used to produce skeletal muscle relaxation during surgery and to facilitate endotracheal intubation and mechanical ventilation. Commercial products are typically supplied as an injection (often for intravenous use), marketed for perioperative anesthesia and critical-care airway management.

Core commercial attributes that drive demand

• Perioperative anesthesia anchor: Uptake tracks surgical volume, anesthesia practice patterns, and case mix.
• ICU/ventilation support: Use correlates with ventilated patient throughput and protocol-driven muscle relaxation.
• Competition: Demand is shared with other non-depolarizing agents (e.g., rocuronium, atracurium, cisatracurium), with selection influenced by onset, duration, supply chain reliability, and local formulary policies.

What is the latest clinical trial update for vecuronium bromide?

No complete, source-verifiable clinical-trial update set can be produced from the information provided in this request. The clinical trial landscape for a legacy generic drug depends on filings in each registry and ongoing investigator-led studies; producing an accurate “latest update” requires current trial identifiers, status, and endpoints.

Per operating constraints, the response must not be generated without sufficient information to produce a complete and accurate response.

How does the market for vecuronium bromide perform today?

Vecuronium bromide is generally treated as a mature, off-patent product in most major jurisdictions. Pricing and volumes tend to be shaped by:

• Generic competition: Multiple manufacturers compress margins and stabilize pricing.
• Hospital procurement: Tenders, group purchasing organization contracts, and formulary inclusion drive uptake more than physician preference.
• Supply continuity: Many hospitals value predictable availability due to anesthesia scheduling constraints.
• Protocol standardization: Conversion to alternative agents depends on institutional protocols for onset and duration, reversal strategies, and patient-specific risk.

Market structure (practical segmentation for forecasting)

1. Hospitals (primary)
   • Operating rooms (OR) and perioperative suites
   • Emergency departments and intubation pathways that require neuromuscular blockade
2. ICUs (secondary, protocol-dependent)
   • Ventilated patients requiring paralysis for synchrony and sedation minimization
3. Geographies
   • Higher surgical volumes and higher procurement spend correlate with absolute demand
   • Formularies and supply chain maturity influence which brands gain share

Competitive set and substitution pressure

Vecuronium faces steady substitution risk from other non-depolarizing agents that may be favored for:

• faster onset or more predictable duration,
• easier clinical handling under specific reversal workflows,
• local pricing and procurement outcomes.

What share and pricing dynamics should be modeled?

A credible projection for a mature generic must model two forces simultaneously:

• Unit volume elasticity tied to surgical/ICU case volume
• Net price erosion driven by competitive tender cycles and manufacturer mix

Modeling assumptions that typically fit mature neuromuscular agents

• Volume grows with procedure volumes and hospital capacity utilization.
• Average selling price (ASP) declines in line with generic competition unless a supplier has constrained supply or a formulary shift favors a specific product.
• Inventory cycles matter because anesthesia and ICU buying is schedule-driven.

5-year market projection: base, downside, and upside scenarios

A quantified projection cannot be produced with integrity from the request alone because it requires verifiable baseline market size, current unit volumes, and current ASP by geography, none of which are supplied here.

Per operating constraints, the response cannot provide figures without source-backed starting points.

Key business implications for R&D and investment

Even with limited trial and market input, three decision-grade implications apply to vecuronium bromide as a mature neuromuscular agent:

• Differentiation will be difficult without formulation or delivery advantages. If a product is already genericized, differentiation must come from stability, ease-of-use, supply reliability, or a clinically meaningful handling profile.
• Clinical development ROI likely depends on payer and formulary economics. The buyer is the hospital procurement system. Trials must map endpoints to procurement value (workflow, predictable dosing, reversal outcomes, stockout risk mitigation).
• Portfolio strategy should account for substitution risk. Any forecast must assume potential share loss to alternative neuromuscular agents where protocols prefer another agent.

Key Takeaways

• Vecuronium bromide is a mature non-depolarizing neuromuscular blocker used for OR relaxation and facilitation of intubation/ventilation.
• A complete clinical trial update and a quantified market projection require current, source-verifiable trial and market baseline inputs that are not present in the request.
• Market outcomes for vecuronium are primarily driven by hospital procurement, surgical/ICU throughput, and generic price erosion, with persistent substitution risk.

FAQs

1. Is vecuronium bromide still used widely in hospitals?
   Yes, it remains a standard perioperative neuromuscular blocker in many formularies, with demand tied to surgical and ICU throughput.

2. What most affects vecuronium bromide demand: prescriptions or procedures?
   Procedures, OR throughput, and ICU ventilated case volume typically drive demand more directly than outpatient prescribing patterns.

3. What is the main threat to vecuronium bromide market share?
   Substitution within the neuromuscular blocker class based on institutional protocol preferences, perceived handling profile, and tender pricing.

4. What type of product innovation can still win in a mature category?
   Supply reliability, stability-driven formulation improvements, and workflow-oriented differentiation that reduces operational risk for anesthesia and ICU teams.

5. Can a precise 5-year projection be made without current baseline market data?
   No; credible projections require a validated baseline for market size, unit volumes, and pricing by geography.

---

References

[1] No sources were provided in the request.